Intensity Therapeutics presented new data recently re its ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate.
INT230-6 is designed for direct intratumoral injection. It was discovered using Intensity’s proprietary DfuseRx℠ technology platform. The drug is comprised of two proven, potent anti-cancer agents, cisplatin and vinblastine, and a penetration enhancer molecule that helps disperse the drugs throughout tumors for diffusion into cancer cells.
“We have seen good disease control rate in highly refractory patients having several different cancer types,” Lewis H. Bender, president and CEO of Intensity, told BioCT. more